source
- AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus KeytrudaAstraZeneca has stopped a phase 3 trial of volrustomig in lung cancer based on interim efficacy data, narrowing the opportunity for a bispecific designed to replace current immune checkpoint inhibi…Fierce Biotech · 6h ago↗ source
- FDA approves Bristol Myers' first oral therapy for advanced multiple myeloma, a new drug classThe U.S. Food and Drug Administration gave its nod to an oral medication from Bristol Myers Squibb for patients with advanced multiple myeloma. The drug represents the first member of a novel clas…